Five Prime Therapeutics Terminates Research and Collaboration Agreement with INBRX 110 LP

Five Prime Therapeutics Terminates Research and Collaboration Agreement with INBRX 110 LP

Five Prime Therapeutics (FPRX) disclosed in a regulatory filing that it has delivered to INBRX 110 LP, or Inhibrx, a written notice of termination of the research collaboration and license agreement between the companies. Under this agreement, FivePrime obtained from Inhibrx an exclusive, worldwide license to antibodies to glucocorticoid-induced tumor necrosis factor receptor for therapeutic and diagnostic uses, and an exclusive option to obtain exclusive, worldwide licenses to multi-specific antibodies […]

Read More ˃